Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: Enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model

Sudhanshu P. Raikwar, Constance J. Temm, Nandita S. Raikwar, Chinghai Kao, Bruce Molitoris, Thomas Gardner

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Angiogenesis is essential for prostate cancer development and metastasis. Antiangiogenic therapy targeting tumor neovasculature, therefore, represents a promising approach for prostate cancer treatment. We hypothesized that adenoviral-mediated delivery of a combination of antiangiogenic factors might have an enhanced antitumor response. We developed the adenoviral vectors Ad-hEndo-angio, expressing a unique, chimeric human endostatin-angiostatin fusion protein, and Ad-sTie2, expressing a soluble form of endothelium-specific receptor tyrosine kinase Tie2. Matrigel angiogenesis assays using Ad-hEndo-angio revealed significant inhibition of tubular network formation and endothelial sprouting compared to Ad-sTie2. In vivo studies in a bilateral PC-3 tumor xenograft model following either intratumoral or systemic administration of Ad-hEndo-angio led to enhanced tumor growth suppression compared to Ad-sTie2. A novel finding is that an intratumoral, combination therapy employing one-half the dose of Ad-hEndo-angio as well as Ad-sTie2 led to a complete regression of the injected, as well as the contralateral uninjected, tumor and prolonged the tumor-free survival in 80% of the animals. In addition, a novel, real-time, intravital imaging modality was used to monitor antiangiogenic responses following adenoviral-mediated gene transfer. These results suggest that a combinatorial antiangiogenic gene therapy approach involving Ad-hEndo-angio and Ad-sTie2 could become a novel form of treatment for localized human prostate cancer.

Original languageEnglish
Pages (from-to)1091-1100
Number of pages10
JournalMolecular Therapy
Volume12
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Angiostatins
Endostatins
Prostate
Growth
Prostatic Neoplasms
Neoplasms
Receptor Protein-Tyrosine Kinases
Therapeutics
Heterografts
Genetic Therapy
Endothelium
Neoplasm Metastasis
Survival
Genes
Proteins

Keywords

  • Angiogenesis
  • Angiostatin
  • Endostatin
  • Intravital imaging
  • Prostate cancer
  • Tie2

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2 : Enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. / Raikwar, Sudhanshu P.; Temm, Constance J.; Raikwar, Nandita S.; Kao, Chinghai; Molitoris, Bruce; Gardner, Thomas.

In: Molecular Therapy, Vol. 12, No. 6, 12.2005, p. 1091-1100.

Research output: Contribution to journalArticle

@article{e9d17ed91700448eb44657f24094eae2,
title = "Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: Enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model",
abstract = "Angiogenesis is essential for prostate cancer development and metastasis. Antiangiogenic therapy targeting tumor neovasculature, therefore, represents a promising approach for prostate cancer treatment. We hypothesized that adenoviral-mediated delivery of a combination of antiangiogenic factors might have an enhanced antitumor response. We developed the adenoviral vectors Ad-hEndo-angio, expressing a unique, chimeric human endostatin-angiostatin fusion protein, and Ad-sTie2, expressing a soluble form of endothelium-specific receptor tyrosine kinase Tie2. Matrigel angiogenesis assays using Ad-hEndo-angio revealed significant inhibition of tubular network formation and endothelial sprouting compared to Ad-sTie2. In vivo studies in a bilateral PC-3 tumor xenograft model following either intratumoral or systemic administration of Ad-hEndo-angio led to enhanced tumor growth suppression compared to Ad-sTie2. A novel finding is that an intratumoral, combination therapy employing one-half the dose of Ad-hEndo-angio as well as Ad-sTie2 led to a complete regression of the injected, as well as the contralateral uninjected, tumor and prolonged the tumor-free survival in 80{\%} of the animals. In addition, a novel, real-time, intravital imaging modality was used to monitor antiangiogenic responses following adenoviral-mediated gene transfer. These results suggest that a combinatorial antiangiogenic gene therapy approach involving Ad-hEndo-angio and Ad-sTie2 could become a novel form of treatment for localized human prostate cancer.",
keywords = "Angiogenesis, Angiostatin, Endostatin, Intravital imaging, Prostate cancer, Tie2",
author = "Raikwar, {Sudhanshu P.} and Temm, {Constance J.} and Raikwar, {Nandita S.} and Chinghai Kao and Bruce Molitoris and Thomas Gardner",
year = "2005",
month = "12",
doi = "10.1016/j.ymthe.2005.07.690",
language = "English",
volume = "12",
pages = "1091--1100",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2

T2 - Enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model

AU - Raikwar, Sudhanshu P.

AU - Temm, Constance J.

AU - Raikwar, Nandita S.

AU - Kao, Chinghai

AU - Molitoris, Bruce

AU - Gardner, Thomas

PY - 2005/12

Y1 - 2005/12

N2 - Angiogenesis is essential for prostate cancer development and metastasis. Antiangiogenic therapy targeting tumor neovasculature, therefore, represents a promising approach for prostate cancer treatment. We hypothesized that adenoviral-mediated delivery of a combination of antiangiogenic factors might have an enhanced antitumor response. We developed the adenoviral vectors Ad-hEndo-angio, expressing a unique, chimeric human endostatin-angiostatin fusion protein, and Ad-sTie2, expressing a soluble form of endothelium-specific receptor tyrosine kinase Tie2. Matrigel angiogenesis assays using Ad-hEndo-angio revealed significant inhibition of tubular network formation and endothelial sprouting compared to Ad-sTie2. In vivo studies in a bilateral PC-3 tumor xenograft model following either intratumoral or systemic administration of Ad-hEndo-angio led to enhanced tumor growth suppression compared to Ad-sTie2. A novel finding is that an intratumoral, combination therapy employing one-half the dose of Ad-hEndo-angio as well as Ad-sTie2 led to a complete regression of the injected, as well as the contralateral uninjected, tumor and prolonged the tumor-free survival in 80% of the animals. In addition, a novel, real-time, intravital imaging modality was used to monitor antiangiogenic responses following adenoviral-mediated gene transfer. These results suggest that a combinatorial antiangiogenic gene therapy approach involving Ad-hEndo-angio and Ad-sTie2 could become a novel form of treatment for localized human prostate cancer.

AB - Angiogenesis is essential for prostate cancer development and metastasis. Antiangiogenic therapy targeting tumor neovasculature, therefore, represents a promising approach for prostate cancer treatment. We hypothesized that adenoviral-mediated delivery of a combination of antiangiogenic factors might have an enhanced antitumor response. We developed the adenoviral vectors Ad-hEndo-angio, expressing a unique, chimeric human endostatin-angiostatin fusion protein, and Ad-sTie2, expressing a soluble form of endothelium-specific receptor tyrosine kinase Tie2. Matrigel angiogenesis assays using Ad-hEndo-angio revealed significant inhibition of tubular network formation and endothelial sprouting compared to Ad-sTie2. In vivo studies in a bilateral PC-3 tumor xenograft model following either intratumoral or systemic administration of Ad-hEndo-angio led to enhanced tumor growth suppression compared to Ad-sTie2. A novel finding is that an intratumoral, combination therapy employing one-half the dose of Ad-hEndo-angio as well as Ad-sTie2 led to a complete regression of the injected, as well as the contralateral uninjected, tumor and prolonged the tumor-free survival in 80% of the animals. In addition, a novel, real-time, intravital imaging modality was used to monitor antiangiogenic responses following adenoviral-mediated gene transfer. These results suggest that a combinatorial antiangiogenic gene therapy approach involving Ad-hEndo-angio and Ad-sTie2 could become a novel form of treatment for localized human prostate cancer.

KW - Angiogenesis

KW - Angiostatin

KW - Endostatin

KW - Intravital imaging

KW - Prostate cancer

KW - Tie2

UR - http://www.scopus.com/inward/record.url?scp=28444498320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444498320&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.07.690

DO - 10.1016/j.ymthe.2005.07.690

M3 - Article

C2 - 16169279

AN - SCOPUS:28444498320

VL - 12

SP - 1091

EP - 1100

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -